HGH Fragment 176-191Growth HormoneSafety Rating 7/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors · per 5mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| Deus MedicalBest $/mgCOA on requestOut of stock | $43.20 | $4.32 | Apr 17, 2026 | Buy → |
| Swiss ChemsCOA ✓ · 3P | $38.36 | $7.67 | Apr 17, 2026 | Buy → $25 off $100+·auto |
| SomaChemsCOA ✓ · 3P | $39.99 | $8.00 | May 14, 2026 | Buy → |
| Biotech PeptidesCOA unknown | $44.00 | $8.80 | May 14, 2026 | Buy → |
| Core PeptidesCOA ✓ · 3P | $44.00 | $8.80 | Apr 16, 2026 | Buy → |
Overview
About HGH Fragment 176-191
Mechanism of action
C-terminal fragment of HGH (amino acids 176–191); selectively activates fat cell beta-3 adrenergic receptors to stimulate lipolysis; inhibits lipogenesis without affecting IGF-1 or causing hyperglycemia.
Safety profile
Minimal. Injection site redness, rare headache. No glucose dysregulation. No cancer risk from IGF-1 elevation. · Similar to AOD-9604; designed to avoid full GH side effects; no IGF-1 elevation; well-tolerated anecdotally
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops HGH Fragment 176-191 below your target.
Related pages
More on HGH Fragment 176-191
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- HGH Fragment 176-191 (AOD9604), a 16-amino-acid C-terminal fragment of hGH with a Tyr→Phe substitution at position 177, produces fat-selective lipolytic effects without binding the hGH receptor, without stimulating IGF-1 production, and without affecting insulin sensitivity or promoting tissue growth — demonstrating that the growth and metabolic functions of hGH are structurally separable.
- Chronic treatment with AOD9604 in obese mice reduced body weight, increased in vivo fat oxidation, and elevated plasma glycerol (index of lipolysis); crucially, beta-3 adrenergic receptor knockout mice were unresponsive to AOD9604, identifying beta-3 AR upregulation as an obligate downstream mechanism for long-term lipolytic effects.